-
11:22:41 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

KDNY Stock News

05/20/22 10:25 AM
Nasdaq : KDNY
clinical trial
Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th European Renal Association (ERA) Congress 2022
The AFFINITY IgAN cohort of 20 patients is fully enrolled, with 70% of patients in the study having baseline proteinuria over one gram per day despite maximal RAS inhibitor treatment, representing an IgAN patient population at high risk for progression Atrasentan was well-tolerated with no
RHEA-AI
neutral
05/19/22 2:05 AM
Nasdaq : KDNY
clinical trial
Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022
All patients with IgAN in Cohort 1 have transitioned to subcutaneous (SC) dosing, and BION-1301 remains well-tolerated, with no serious adverse events (SAEs) and no treatment discontinuations due to adverse events (AEs) BION-1301 continues to demonstrate rapid and sustained reductions in
RHEA-AI
negative